Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCERTAIN-TRD
NCT02977299Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of aripiprazole and venlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Jul 2017; status: completed.
02
Drugs
aripiprazolevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02977299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977299.